Anixa Biosciences, Inc. (ANIX)
| Market Cap | 92.30M -35.2% |
| Revenue (ttm) | n/a |
| Net Income | -10.38M |
| EPS | -0.31 |
| Shares Out | 34.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 228,408 |
| Open | 2.750 |
| Previous Close | 2.670 |
| Day's Range | 2.630 - 2.818 |
| 52-Week Range | 2.320 - 5.457 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 9.75 (+267.23%) |
| Earnings Date | Sep 9, 2026 |
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to addr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 267.23% from the latest price.
News
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") ...
Anixa Biosciences reports first case of stable disease in CAR-T trial
Anixa Biosciences (ANIX) announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stabl...
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limit...
Anixa Biosciences says second patient treated in CAR-T ovarian cancer trial
Anixa Biosciences (ANIX) announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy...
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Followin...
Anixa Biosciences price target lowered to $6 from $7 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Anixa Biosciences (ANIX) to $6 from $7 and keeps a Buy rating on the shares after the company announced…
Anixa Biosciences granted first Australian patent for breast cancer vaccine
Anixa Biosciences (ANIX) announced that IP Australia has issued Patent Number 2020221280 related to Anixa’s breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This compositi...
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global in...
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A robust clinical pipeline features a novel CAR-T therapy for ovarian cancer and a breast cancer vaccine, both showing promising early results. Strategic partnerships and a strong financial position support low cash burn and future commercialization plans.
Anixa Biosciences Slides: Corporate presentation
Anixa Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...
Anixa Biosciences Quarterly report: Q3 2026
Anixa Biosciences has published its Q3 2026 quarterly earnings report on September 9, 2026.
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswir...
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, li...
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Breas...
Anixa Biosciences granted Australian patent for breast cancer vaccine
Anixa Biosciences (ANIX) announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa’s breast cancer vaccine technology. This patent, exclusively licensed from Clev...
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast cancer...
Anixa Biosciences, Moffitt Cancer advance ovarian cancer CAR-T trial
Anixa Biosciences (ANIX) announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T th...
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg followin...
Anixa Biosciences assumed with a Buy at D. Boral Capital
D. Boral Capital analyst Patrick McCann assumed coverage of Anixa Biosciences (ANIX) with a Buy rating and $10 price target The firm says recent presentations highlighted final Phase 1 results…
Anixa Biosciences granted first Korean patent for breast cancer vaccine
Anixa Biosciences (ANIX) announced that the Korean Ministry of Intellectual Property has issued Patent Number 10-2960889 related to Anixa’s breast cancer vaccine technology. This composition-of-matter...
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate Expands global intellectual pr...
Anixa Biosciences reports results from two clinical-stage immunotherapy programs
Anixa Biosciences (ANIX) announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy symposium this week. The pre...
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, l...